After one year, Yahoo CEO Marissa Mayer has brought the company back from the brink of irrelevance; whether she can return Yahoo to its former glory has been an open question. But there is one key area in which Yahoo has surged ahead of even Google, and that could change everything...
Stocks to Buy 2013
- Best Stocks to Buy Now: A Money Morning Weekly Roundup
- Here's the Key to How the Stock Market Will Move This Week
- Best Stocks to Buy Now: A Weekly Round-up from Money Morning
- Apple (Nasdaq: AAPL) Stock Hits $500 Thanks to Carl Icahn
- These Dividend-Paying Stocks Deliver Yield and Growth
- The Best Stocks to Buy Now: A Weekly Roundup
- Buy, Sell or Hold: Out of Staples (Nasdaq: SPLS)
- Stocks To Buy Now: Profit from Blockbuster New Drugs in 2013
- Stocks to Buy in 2013 Using the "Best Six Months Strategy'
In addition, the U.S. Federal Reserve's decision to taper or not remains at the forefront of investors' minds. Friday's August jobs report might provide more clarity on the central's bank next move, which will be shared - or again teased - at the Sept. 17-18 Federal Open Market Committee (FOMC) meeting.
That's why Money Morning Chief Investment Strategist Keith Fitz-Gerald spoke on Monday with FOX Business' Charles Payne of "Varney & Co."about just how low the stock market can go.
Fitz-Gerald looks at the stock market's support and resistance levels, and gives us a good picture of what to expect in the week ahead - and much more. He looks ahead to the Fed's Jackson "Black" Hole summit, and speculates on when the Fed's reindeer games will run out of gas.
It was a rocky week for markets- but if you know the best stocks to buy now, your portfolio is in good shape...
Last week, the Dow lost 2.23%, or 344 points, to finish at 15,081.47, and the Standard & Poor's 500 fell 2.1% to 1,655.38.
You see, Tuesday afternoon, in a single tweet, the legendary 77-year-old activist investor added more than $17.26 billion to Apple's market cap. At 2:21 p.m., pre-tweet, AAPL stock was trading at $475. Following the tweet, shares shot up to $494, before settling the day at $489.57.
When you think of growth profit plays you do not ordinarily think they could also make for solid dividend-paying stocks as well.
Growth stocks are high-flying market darlings with some exciting new product or service that is driving spectacular earnings growth.
Here's what we learned in the past week on our regular hunt for the best stocks to buy now: investors have more access to biotech's best investments, earnings reports are clearly separating winners from losers, and cybersecurity is looking even more profitable than before.
First, let's start with earnings...
Staples (Nasdaq: SPLS) has increased a whopping 40% this year, but Money Morning analyst David Mamos warns these gains are in danger.
One sector offering stocks to buy now is an industry that's been prepping for huge product deliveries in 2013.
I'm talking about Big Pharma.
After being pummeled by generic rivals for the past few years, a few big pharmaceutical companies are fighting back with a new wave of blockbuster drugs that will hit the market in 2013.
More than ever, Big Pharma companies need new revenue streams to battle the "patent cliff - replacing fading profits from drugs that spawned generic competition.
Last year alone, the industry suffered from the expiration of patents for such lucrative name-brand drugs as AstraZeneca PLC's (NYSE ADR: AZN) Seroquel, Pfizer Inc.'s (NYSE: PFE) Lipitor and Wyeth's Protonix, which total accounted for nearly $36 billion in U.S. sales in 2011 and 2012.
But help is on the way.
Pharmaceutical firms logged 39 new drug approvals last year - the most since 1996 - and there are signs the trend could continue through 2013, according to Reuters.
Drugmakers are betting that a new wave of medicines for cancer, diabetes and heart disease will shape up as tomorrow's blockbusters.
European drugmakers, for example, have the potential to deliver new drugs with peak annual sales of $64 billion in 2013-2015 while patent losses will be only $12 billion, according to Deutsche Bank AG (NYSE: DB) estimates.
No doubt about it - Big Pharma is taking aim at generics with both barrels.
That could mean fat profits for savvy investors who focus on high-quality companies with strong late-stage pipelines.
Here are three that are loaded for 2013.
Stocks to Buy: Big Biotech Delivers Big Profits
Innovations in biological science - or biotech - are evolving at the speed of light.In fact, leading edge biotech products and breakthroughs are saving thousands of lives every day.
And business is booming for one biotech bellwether ...
It's called the "best six months strategy." Simply put, the markets -- and the Dow Jones Industrial Average in particular -- perform much better in the November-April period than the May-October period.
The May-October slump, in fact, gave rise to the old investing axiom, "sell in May and go away."
But most investors don't realize they can use the consistency of the pattern, and its oscillating nature, as an investing strategy.
"We've found that most of the market's gains are made from November to April, whereas you either go down or are flat from May through October," Jeff Hirsch, editor-in-chief of the Stock Trader's Almanac, said in an interview on Breakout.
The historic discrepancy is larger than one might think. Stock Trader's Almanac analyzed the performance of the Dow Jones from 1950 through 2011 and found that the November-April period showed an average increase of 7.5%, compared to a meager 0.4% average gain for the May-October period.
"It's a pretty robust strategy," Hirsch said. "It's worked over the years. It's one of the most consistent things we've seen."
Still, the best-six month strategy is not as easy as simply selling on May 1 and buying on Nov. 1. Investors need to keep an eye on macro events and use technical indicators for the best times to get in and out. In some years, Hirsch said, it's better to re-enter the market in October.